1965
CONCEPTION
Nigel Manning, Dean of the Victorian College of Pharmacy, and colleagues conceived the idea of establishing an institute dedicated to industrial pharmacy. This vision became part of the College’s development strategy in 1970.
Our journey began over 50 years ago, driven by a vision to advance pharmaceutical manufacturing in Australia. Here are some of the key milestones that have shaped IDT into the CDMO we are today
Nigel Manning, Dean of the Victorian College of Pharmacy, and colleagues conceived the idea of establishing an institute dedicated to industrial pharmacy. This vision became part of the College’s development strategy in 1970.
The Institute of Drug Technology Limited (IDT) was officially established as an independent company, operating in partnership with the Victorian College of Pharmacy. From the outset, IDT focused on delivering high-quality contract and consultancy services, leveraging academic expertise and a small team of dedicated scientists.
IDT established a reputation for high-quality contract and consultancy services, supporting the growth of Australia’s pharmaceutical industry.
Dr Graeme Blackman, then a Senior Lecturer at the Victorian College of Pharmacy, was appointed Chairman and Executive Director. Under his guidance, the company entered a new phase of growth.
Listed on the ASX and acquired Nicholas Kiwi Central Laboratories (NKCL).
Opened a new high-potency API facility in Boronia following a >$20 million investment; expanded long-term manufacturing collaboration with Pfizer Australia.
FDA restored IDT’s facility inspection classification to VAI (Voluntary Action Indicated), clearing the way for applications referencing IDT’s site.
TGA granted a sterile licence for aseptic vial filling; later that year IDT successfully manufactured Australia’s first mRNA COVID-19 vaccine candidate for a Monash clinical trial.
TGA expanded IDT’s sterile licence to allow manufacture and release of injectable medicines for clinical trials in Australia and overseas.
Victorian Government backed IDT to establish Australia’s first accredited ADC (antibody-drug conjugate) manufacturing facility in Boronia; the Ehrlich Bioconjugation Centre officially opened in 2025.
Recommissioned a 4,000 L plant — becoming Australia’s largest small-molecule API facility.
